NCT02448225View on ClinicalTrials.gov

18F-FSPG PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

June 16, 2015

Primary Completion Date

August 2, 2021

Study Completion Date

October 10, 2022

Conditions
Lung CarcinomaSolitary Pulmonary NoduleCigarette Smoking Behavior
Interventions
PROCEDURE

Computed Tomography

Undergo 18F-FDG PET/CT - standard of care

PROCEDURE

Computed Tomography

Undergo 18F-FSPG PET/CT

RADIATION

fluorodeoxyglucose F-18

Undergo 18F-FDG PET/CT - standard of care

DRUG

Fluorine F 18 L-glutamate Derivative BAY94-9392

Undergo 18F-FSPG PET/CT

OTHER

Laboratory Biomarker Analysis

Correlative studies

PROCEDURE

Positron Emission Tomography

Undergo 18F-FDG PET/CT - standard of care

PROCEDURE

Positron Emission Tomography (PET)

Undergo 18F-FSPG PET/CT

Trial Locations (2)

37212

Tennessee Valley Health System Nashville, Nashville

37232

Vanderbilt-Ingram Cancer Center, Nashville

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Vanderbilt-Ingram Cancer Center

OTHER

NCT02448225 - 18F-FSPG PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules | Biotech Hunter | Biotech Hunter